Bosh sahifa207940 • KRX
add
Samsung Biologics Co Ltd
Yopilish kursi
1 116 000,00 ₩
Kunlik diapazon
1 110 000,00 ₩ - 1 145 000,00 ₩
Yillik diapazon
721 000,00 ₩ - 1 209 000,00 ₩
Bozor kapitalizatsiyasi
79,71 trln KRW
Oʻrtacha hajm
76,58 ming
Narx/foyda
73,58
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,26 trln | 17,04% |
Joriy xarajat | 334,17 mlrd | 87,16% |
Sof foyda | 321,49 mlrd | 10,60% |
Sof foyda marjasi | 25,59 | -5,50% |
Har bir ulushga tushum | 4,52 ming | 10,60% |
EBITDA | 476,48 mlrd | -3,14% |
Amaldagi soliq stavkasi | 14,04% | — |
Balans
Jami aktivlari
Jami passivlari
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,33 trln | -35,26% |
Jami aktivlari | 17,34 trln | 8,04% |
Jami passivlari | 6,43 trln | 3,47% |
Umumiy kapital | 10,90 trln | — |
Tarqatilgan aksiyalar | 71,17 mln | — |
Narxi/balansdagi bahosi | 7,28 | — |
Aktivlardan daromad | 4,88% | — |
Kapitaldan daromad | 6,80% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 321,49 mlrd | 10,60% |
Operatsiyalardan naqd pul | 389,56 mlrd | -53,23% |
Sarmoyadan naqd pul | -1,07 trln | -138,92% |
Moliyadan naqd pul | 514,35 mlrd | 280,15% |
Naqd pulning sof oʻzgarishi | -149,00 mlrd | -267,89% |
Boʻsh pul | -30,00 mlrd | -107,16% |
Haqida
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Tashkil etilgan
2011
Xodimlar soni
4 744
